| Agonist . | EC50 (µM) . | nH . | Imax agonist/Imax ATP (%) . | n . |
|---|---|---|---|---|
| ATP | 32 ± 4 | 1.4 ± 0.1 | n/a | 15 |
| LNA-ATP | 27 ± 1 | 1.8 ± 0.1 | 66 ± 1 | 9 |
| C2′-F-dATP | 52 ± 6** | 2.1 ± 0.1*** | 60 ± 2 | 8 |
| Ara-ATP | >100 | ND | ND | 6 |
| C3′-dATP | 83 ± 4**** | 2.6 ± 0.1**** | 67 ± 2 | 8 |
| C2′-dATP | >300 | ND | ND | 9 |
| C2′-C3′-ddATP | ND | ND | ND | ND |
| Agonist . | EC50 (µM) . | nH . | Imax agonist/Imax ATP (%) . | n . |
|---|---|---|---|---|
| ATP | 32 ± 4 | 1.4 ± 0.1 | n/a | 15 |
| LNA-ATP | 27 ± 1 | 1.8 ± 0.1 | 66 ± 1 | 9 |
| C2′-F-dATP | 52 ± 6** | 2.1 ± 0.1*** | 60 ± 2 | 8 |
| Ara-ATP | >100 | ND | ND | 6 |
| C3′-dATP | 83 ± 4**** | 2.6 ± 0.1**** | 67 ± 2 | 8 |
| C2′-dATP | >300 | ND | ND | 9 |
| C2′-C3′-ddATP | ND | ND | ND | ND |
Concentration–response data (EC50) and Hill coefficient (nH) for ATP and a range of sugar-modified nucleoside triphosphate analogues (shown as mean ± SEM). Relative efficacy expressed as maximal current compared to that elicited by 1 mM of ATP and number of experiments (n) and are also shown (n/a: not applicable; ND, not determined). Significant differences were determined by one-way ANOVA with Dunnett’s test. **, P < 0.01; ***, P = 0.0001; ****, P < 0.0001.